Shuttle Pharmaceuticals – TheNewswire - (SHPH), has announced that it has been awarded patents in the U.S. and Hong Kong for its radiation sensitizing HDAC inhibitor technology platform, which is focused on reducing side effects and improving outcomes for cancer patients treated with radiation therapy.

 

Approximately 800,000 patients in the US are treated with radiation therapy for their cancers. The number of patients being treated with radiation therapy is expected to grow by more than 22% over the next five years.

 

Treatment with HDAC inhibitors allows regulation of gene expression by blocking HDAC enzyme activity and allowing genes to be "turned on" to express proteins involved in regulation of the cell cycle, DNA damage response and immune activation. Inhibiting HDAC enzymes can turn on tumor suppressor genes to help control cell division and slow down cancer progression. 

 

Chief Executive Officer of Shuttle Pharmaceuticals Dr. Dritschilo stated: "We are developing our platform with the goal of being on the leading-edge in helping cancer patients treated with radiation therapy have the best possible outcomes and dramatically improve their quality of life."

 

Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy.

 

Shares of Shuttle Pharmaceuticals trade on the NASDAQ under the ticker symbol SHPH. For more information visit www.greenstocknews.com

  

Disclaimer

 

This content is not financial advice and is for information, education and entertainment purposes only. Green Stock News is not responsible for any losses related to the financial decisions made by you. Video content and other materials including web content are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Green Stock News is not responsible for any gains or losses that result from the opinions expressed in this video or materials that it publishes electronically.

 

View original video news clips here: https://greenstocknews.com/green-stock-newswire 

  

Copyright (c) 2022 TheNewswire - All rights reserved.